U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07412054) titled 'Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC' on Feb. 09.
Brief Summary: The goal of this clinical trial is to learn whether adding branched-chain amino acids (BCAAs) to lenvatinib and pembrolizumab improves treatment outcomes in adults with unresectable hepatocellular carcinoma (HCC). The study will also evaluate the safety of this combination treatment.
The main questions this study aims to answer are:
Does the addition of BCAAs improve the time patients live without their cancer getting worse? Does the combination treatment improve tumor response compared with standard treatment alone? What medical prob...